LLY

1,041.42

-1.74%↓

JNJ

205.2

-0.48%↓

ABBV

224.81

-0.05%↓

UNH

324.69

-0.08%↓

AZN

90.39

-0.24%↓

LLY

1,041.42

-1.74%↓

JNJ

205.2

-0.48%↓

ABBV

224.81

-0.05%↓

UNH

324.69

-0.08%↓

AZN

90.39

-0.24%↓

LLY

1,041.42

-1.74%↓

JNJ

205.2

-0.48%↓

ABBV

224.81

-0.05%↓

UNH

324.69

-0.08%↓

AZN

90.39

-0.24%↓

LLY

1,041.42

-1.74%↓

JNJ

205.2

-0.48%↓

ABBV

224.81

-0.05%↓

UNH

324.69

-0.08%↓

AZN

90.39

-0.24%↓

LLY

1,041.42

-1.74%↓

JNJ

205.2

-0.48%↓

ABBV

224.81

-0.05%↓

UNH

324.69

-0.08%↓

AZN

90.39

-0.24%↓

Search

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.34 -1.47

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.34

Max

1.3900000000000001

Põhinäitajad

By Trading Economics

Sissetulek

-16M

-13M

Müük

-15M

14M

Aktsiakasum

-0.04

Kasumimarginaal

-90.037

Töötajad

103

EBITDA

-16M

-10M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+191.91% upside

Turustatistika

By TradingEconomics

Turukapital

22M

516M

Eelmine avamishind

2.81

Eelmine sulgemishind

1.34

Uudiste sentiment

By Acuity

50%

50%

166 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. dets 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1. dets 2025, 18:51 UTC

Suurimad hinnamuutused turgudel

Shopify Stock Falls on Cyber Monday System Outages

1. dets 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Bargain Hunting -- Market Talk

1. dets 2025, 23:27 UTC

Omandamised, ülevõtmised, äriostud

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1. dets 2025, 23:26 UTC

Omandamised, ülevõtmised, äriostud

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1. dets 2025, 23:25 UTC

Omandamised, ülevõtmised, äriostud

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1. dets 2025, 21:52 UTC

Omandamised, ülevõtmised, äriostud

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1. dets 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1. dets 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1. dets 2025, 21:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. dets 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1. dets 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1. dets 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1. dets 2025, 20:15 UTC

Market Talk

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1. dets 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1. dets 2025, 18:54 UTC

Market Talk

Silver Hits New Record As Momentum Continues -- Market Talk

1. dets 2025, 18:46 UTC

Market Talk

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1. dets 2025, 16:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. dets 2025, 16:41 UTC

Market Talk

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1. dets 2025, 16:20 UTC

Market Talk

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1. dets 2025, 16:00 UTC

Tulu

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1. dets 2025, 15:51 UTC

Omandamised, ülevõtmised, äriostud

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1. dets 2025, 15:47 UTC

Market Talk

Global Equities Roundup: Market Talk

1. dets 2025, 15:47 UTC

Market Talk

Airbus Guidance Is at Risk -- Market Talk

1. dets 2025, 15:46 UTC

Omandamised, ülevõtmised, äriostud

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1. dets 2025, 15:33 UTC

Market Talk

Airbus Selloff May Be Overdone -- Market Talk

1. dets 2025, 15:26 UTC

Market Talk

Warming Forecast Pressures Natural Gas -- Market Talk

1. dets 2025, 15:23 UTC

Market Talk

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1. dets 2025, 14:59 UTC

Omandamised, ülevõtmised, äriostud

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

191.91% tõus

12 kuu keskmine prognoos

Keskmine 3.97 USD  191.91%

Kõrge 6 USD

Madal 1.9 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

166 / 374 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
help-icon Live chat